At the news
? NEUTRALIMPACT 2/10 CLUSTER filed Nov 13, 2026 at 20:03 ET
Two insiders at Oruka Therapeutics, including a director and the SVP of Finance, sold shares under 10b5-1 plans for a combined $173K. The sales are small relative to market cap and appear to be routine, pre-planned transactions, not signaling a material negative event.
- Director Kristine M. Ball sold 1,200 shares for $122K under a 10b5-1 plan on Nov 12.
- SVP of Finance Arjun Agarwal sold 500 shares for $51K under a 10b5-1 plan on Nov 12.
- Total open-market sales of $173K are immaterial relative to market cap (not provided, but under $500K).
- Both sales were pre-planned under 10b5-1 trading plans, reducing the likelihood of opportunistic selling.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access